GC

Genelux Corporation

GNLX·NASDAQ

$3.00

+1.0%
HealthcareBiotechnology

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

At a Glance

Live Snapshot
Market Cap$112.85M
EPS-0.8600
P/E Ratio-3.49
Earnings Date08/06/2026

gnlx

Net Interest Income

Last Annual Value

1.07M

3-Year CAGR

40%

5-Year CAGR

24%

10-Year CAGR

%

GC

Genelux Corporation Competitors Analysis of Net Interest Income

GNLX · NASDAQ
CompanyNet Interest Income
CAGR 3Y
CAGR 5Y
CAGR 10Y
1.07M
N/AN/AN/A 
1.42M
-35.4%N/AN/A
CDXS logo
Codexis, Inc.
NASDAQ:CDXS
-2.19M
N/AN/AN/A
5.53M
N/AN/A154.9%
IVVD logo
Invivyd, Inc.
NASDAQ:IVVD
3.07M
N/AN/AN/A
OABI logo
OmniAb, Inc.
NASDAQ:OABI
2.66M
-19.3%N/AN/A
3.61M
-18.3%174.9%N/A
1.41M
39.0%198.0%N/A
1.80M
N/AN/AN/A
5.92M
30.6%230.6%N/A
8.25M
23.3%N/AN/A
GC

Genelux Corporation Fair Value Envelope

GNLX · NASDAQ

Our analysis suggests that GNLX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3, this represents a potential HIDDEN relative to our calculated worth for Genelux Corporation.

Intrinsic Value
Current Price: $3